ICON PLC (ICLR) Options

Lot going on here ICLR WOOHOOOOOOOOOOOOOOO $400 TARGET PRICE

$ICLR great article Icon Plc Nasdaq Iclr Short Squeeze

ICON is scheduled to report earnings on Thursday and the stock is currently trading near its 52-week high. However, finbox.io fair value data implies that shares are still 18% undervalued:

Six Healthcare Stocks with Nice Upside Potential

ICLR bullish 76.12

bull flag

SEC suspension cancelled.

ICLR: SEC Admin Proceeding still active:

http://www.sec.gov/litigation/admin/2014/34-73406.pdf

Excerpts:
The Securities and Exchange Commission (“Commission”) deems it necessary and appropriate for the protection of investors that public administrative proceedings be, and hereby are, instituted pursuant to Section 12(j) of the Securities Exchange Act of 1934 (“Exchange Act”) against Respondents 21st Century Telesis II, Inc., Agemark Corp., Alnilam Corp., American Centrality Group, Inc., China Feicui Guodian Group Ltd., and Icon Public Ltd. Co


6. Icon Public Ltd. Co. (CIK No. 1060373) is an Irish company located in Dublin, Ireland with a class of securities registered with the Commission pursuant to Exchange Act Section 12(g). Icon Public is delinquent in its periodic filings with the Commission, having not filed any periodic reports since it filed a Form 20-F for the period ended May 31, 2002, which reported a net loss of $87,939 for the prior three months. As of October 16, 2014, the company’s stock (symbol “ICLR”) was quoted on Nasdaq, had four market makers, and was eligible for the “piggyback” exception of Exchange Act Rule 15c2-11(f)(3).

B. DELINQUENT PERIODIC FILINGS

7. As discussed in more detail above, all of the Respondents are delinquent in their periodic filings with the Commission, have repeatedly failed to meet their obligations to file timely periodic reports, and failed to heed delinquency letters sent to them by the Division of Corporation Finance requesting compliance with their periodic filing obligations or, through their failure to maintain a valid address on file with the Commission as required by Commission rules, did not receive such letters.

8. Exchange Act Section 13(a) and the rules promulgated thereunder require issuers of securities registered pursuant to Exchange Act Section 12 to file with the Commission current and accurate information in periodic reports, even if the registration is voluntary under Section 12(g). Specifically, Rule 13a-1 requires issuers to file annual reports, and Rule 13a-13 requires domestic issuers to file quarterly reports.

9. As a result of the foregoing, Respondents failed to comply with Exchange Act Section 13(a) and Rules 13a-1 and/or 13a-13 thereunder.

In view of the allegations made by the Division of Enforcement, the Commission deems it necessary and appropriate for the protection of investors that public administrative proceedings be instituted to determine:

A. Whether the allegations contained in Section II hereof are true and, in connection therewith, to afford the Respondents an opportunity to establish any defenses to such allegations; and,

B. Whether it is necessary and appropriate for the protection of investors to suspend for a period not exceeding twelve months, or revoke the registration of each class of securities registered pursuant to Section 12 of the Exchange Act of the Respondents identified in Section II hereof, and any successor under Exchange Act Rules 12b-2 or 12g-3, and any new corporate names of any Respondents

IT IS HEREBY ORDERED that a public hearing for the purpose of taking
evidence on the questions set forth in Section III hereof shall be convened at a time and place to be fixed, and before an Administrative Law Judge to be designated by further order as provided by Rule 110 of the Commission’s Rules of Practice [17 C.F.R. § 201.110].

IT IS HEREBY FURTHER ORDERED that Respondents shall file an Answer to
the allegations contained in this Order within ten (10) days after service of this Order, as provided by Rule 220(b) of the Commission’s Rules of Practice [17 C.F.R. § 201.220(b)].

If Respondents fail to file the directed Answers, or fail to appear at a hearing after being duly notified, the Respondents, and any successor under Exchange Act Rules 12b-2 or 12g-3, and any new corporate names of any Respondents, may be deemed in default and the proceedings may be determined against them upon consideration of this Order, the allegations of which may be deemed to be true as provided by Rules 155(a), 220(f), 221(f), and 310 of the Commission’s Rules of Practice [17 C.F.R. §§ 201.155(a), 201.220(f), 201.221(f), and 201.310].

This Order shall be served forthwith upon Respondents personally or by certified, registered, or Express Mail, or by other means permitted by the Commission Rules of Practice.

IT IS FURTHER ORDERED that the Administrative Law Judge shall issue an
initial decision no later than 120 days from the date of service of this Order, pursuant to Rule 360(a)(2) of the Commission’s Rules of Practice [17 C.F.R. §201.360(a)(2)].

In the absence of an appropriate waiver, no officer or employee of the
Commission engaged in the performance of investigative or prosecuting functions in this or any factually related proceeding will be permitted to participate or advise in the decision of this matter, except as witness or counsel in proceedings held pursuant to notice. Since this proceeding is not “rule making” within the meaning of Section 551 of the Administrative Procedure Act, it is not deemed subject to the provisions of Section 553 delaying the effective date of any final Commission action.

By the Commission.
Brent J. Fields
Secretary

ICLR SEC Suspension cancelled.

http://www.sec.gov/litigation/suspensions.shtml

ICLR: SEC Suspension:

http://www.sec.gov/litigation/suspensions/2014/34-73405.pdf

Order:

http://www.sec.gov/litigation/suspensions/2014/34-73405-o.pdf

Admin Proceeding:

http://www.sec.gov/litigation/admin/2014/34-73406.pdf

$ICLR DD Notes ~ http://www.ddnotesmaker.com/ICLR

bullish
ascending triangle breakout

$ICLR recent news/filings

## source: finance.yahoo.com

Wed, 10 Sep 2014 12:52:00 GMT ~ Medidata and ICON Join Forces to Bring New Productivity to Capturing Patient Voice in Clinical Trials

[Business Wire] - Medidata , the leading global provider of cloud-based solutions for clinical research in life sciences, and ICON plc, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced a joint initiative designed to bring new efficiencies to the administration of electronic patient-reported outcomes in clinical trials.

read full: http://finance.yahoo.com/news/medidata-icon-join-forces-bring-125200191.html
*********************************************************

Wed, 03 Sep 2014 18:30:00 GMT ~ AMBS: Amarantus Investor Call Highlights Clinical And Commercial Milestones


read full: http://finance.yahoo.com/news/ambs-amarantus-investor-call-highlights-183000366.html
*********************************************************

Tue, 26 Aug 2014 11:06:34 GMT ~ iKang Healthcare Group, Inc. (KANG) Jumps: Stock Surges 10.1%


read full: http://finance.yahoo.com/news/ikang-healthcare-group-inc-kang-110634230.html
*********************************************************

Mon, 25 Aug 2014 11:22:02 GMT ~ Is ICON Public Limited (ICLR) Stock a Solid Choice Right Now?


read full: http://finance.yahoo.com/news/icon-public-limited-iclr-stock-112202155.html
*********************************************************

Sat, 23 Aug 2014 11:00:00 GMT ~ A Shift in Health-Care M&A Activity


read full: http://news.morningstar.com/articlenet/article.aspx?id=662615&SR=Yahoo
*********************************************************


$ICLR charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com


$ICLR company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/ICLR/company-info
Ticker: $ICLR
OTC Market Place: Not Available
CIK code: 0001060955
Company name: ICON plc
Incorporated In: Ireland


$ICLR share structure

## source: otcmarkets.com

Market Value: Not Available
Shares Outstanding: Not Available
Float: Not Available
Authorized Shares: Not Available
Par Value: Not Available
$ICLR extra dd links

Company name: ICON plc
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/ICLR/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/ICLR/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=ICLR+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=ICLR+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=ICLR+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/ICLR/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/ICLR/news - http://finance.yahoo.com/q/h?s=ICLR+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/ICLR/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/ICLR/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/ICLR/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/ICLR/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/ICLR/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/ICLR/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/ICLR/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/ICLR/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=ICLR+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/ICLR
DTCC (dtcc.com): http://search2.dtcc.com/?q=ICON+plc&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=ICON+plc
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=ICON+plc&x=0&y=0

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/ICLR/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/ICLR
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/ICLR/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/ICLR/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/ICLR/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001060955&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/ICLR/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/ICLR/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/ICLR/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/ICLR/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=ICLR&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=ICLR
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/ICLR/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=ICLR+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=ICLR+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=ICLR
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=ICLR
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=ICLR+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/ICLR/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=ICLR+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/ICLR.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=ICLR
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/ICLR/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/ICLR/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/ICLR/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/ICLR/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/ICLR
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/ICLR
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/ICLR:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=ICLR
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=ICLR



$ICLR DD Notes ~ http://www.ddnotesmaker.com/ICLR

News Story
Credit Suisse Starts ICON plc (ICLR) at Outperform
Print
6:44 AM 3/27/2014 - StreetInsider

Credit Suisse initiated coverage on ICON plc (NASDAQ: ICLR) with anOutperform rating and a price target of $55.00.

http://seekingalpha.com/article/1575362-icon-plc-ordinary-shares-iclr-management-discusses-q2-2013-results-earnings-call-transcript

http://seekingalpha.com/article/1372991-icon-public-limited-management-discusses-q1-2013-results-earnings-call-transcript?

6:41 AM ICON plc (ICLR): Q1 EPS of $0.36 beats by $0.02. Revenue of $317M (+26% Y/Y) beats by $14.71M

http://www.marketintelligencecenter.com/articles/269311

ICON Plc (ICLR) Market Cap: $1.96 billion
ICLR is a Contract Research Organization. These organizations are essential to the pharmaceutical industry as they handle the time consuming and messy process of managing the clinical trials necessary for the approval of new medicines. The largest player in the industry is privately held Quintiles, but among the public companies, ICLR appears best positioned for a long, steady climb. ICLR has demonstrated robust growth, with revenue rising from $297 million in 2003 to $1,115 million in 2012, an increase of 275%. ICLR has a global presence and offers laboratory services as well, meaning that they can do just about everything for their clients except create new molecules. We see ICLR as a buy and hold opportunity.

ICON Announces Appointment of Professor William Hall to Board of Directors


12:30 PM 2/21/2013 - Business Wire

DUBLIN--(BUSINESS WIRE)--Feb. 21, 2013-- ICONplc, (NASDAQ: ICLR), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced the appointment of Professor William Hall as a non-executive director.

A renowned expert in infectious diseases and virology, Professor Hall is Chair of Medical Microbiology and Director of the Centre for Research in Infectious Diseases at University College Dublin’s (UCD) School of Medicine and Medical Science. He is also a director of UCD’s National Virus Reference Laboratory and is a consultant microbiologist at St. Vincent’s University Hospital Dublin. Professor Hall also serves as a consultant to the Minister of Heath and Children in the Republic of Ireland, providing input on a number of topics including influenza pandemic preparedness and bioterrorism.

Prior to his tenure at UCD, Professor Hall was Professor and Head of the Laboratory of Medical Virology, Senior Physician and Director of the Clinical Research Centre at the Rockefeller University in New York. He has also served as an Assistant and Associate Professor of Medicine at Cornell University.

Professor Hall is a board member of The Atlantic Philanthropies and is a co-founder of the Global Virus Network.

“We are delighted to welcome Professor Hall to the ICON Board,” commented Chairman, Mr. Thomas Lynch. “His knowledge and expertise in virology and infectious diseases, coupled with his international research collaborations in these fields will complement the strengths and talents of our existing board members.”

The information contained in this release is as of 21stFebruary 2013. The statements made in this press release may contain forward-looking statements that involve a number of risks and uncertainties. A description of risks and uncertainties relating to ICON and its business can be found in ICON’s Annual Report for the fiscal year ended December 31, 2011 and in the forms filed with the US Securities and Exchange Commission, including the Forms 20-F, F-1, S-8 and F-3. ICON disclaims any intent or obligation to update these forward-looking statements.

ICON plc is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. The company specialises in the strategic development, management and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies. With headquarters in Dublin, Ireland, ICON currently, operates from 79 locations in 37 countries and has approximately 10,045 employees. Further information is available at www.iconplc.com.

Source: ICON plc

ICON/ICLR-F




Source: ICON plc

ICON plc
Investor Relations 1-888-381-7923
or
Brendan Brennan Chief Financial Officer
+ 353 –1-291-2000
or
Sam Farthing VP Investor Relations
+ 353 –1-291-2000
or
Simon Holmes EVP Investor Relations and Corporate Development
+ 353 –1-291-2000

Jeffries raises P/T to $33.50, Raymond James raises it to STRONG BUY

ICON To Acquire Clinical Trial Services Division of Cross Country Healthcare Inc

ICON To Acquire Clinical Trial Services Division of Cross Country Healthcare Inc.

Acquisition Expands ICON’s Global Resourcing, FSP and Safety Capabilities

Dublin, Ireland, 4th February, 2013 – ICON plc, (NASDAQ: ICLR; ISIN: IE0005711209), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced that it has agreed, subject to certain closing conditions, to acquire the Clinical Trial Services Division of Cross Country Healthcare, Inc. (NASDAQ:CCRN), for a cash consideration of $52 million, plus an earn-out of up to $3.75 million related to certain performance-based milestones. The transaction is expected to close within the next 30 days.

Cross Country Healthcare’s Clinical Trial Services Division includes leading US resourcing providers, ClinForce and Assent Consulting, whose services include contract staffing, permanent placement and functional service provision. The division also includes AKOS, a leading US and EU provider of pharmacovigilance and drug safety services. ClinForce and Assent will be combined with ICON’s FSP division, DOCS, creating a leader in global resourcing and FSP, while AKOS will enhance the services offered by ICON’s medical and safety services team.

Commenting on the acquisition, Ciaran Murray, CEO at ICON plc, said: “The demand for flexible resourcing solutions continues to grow as biopharma companies employ a range of outsourcing models to meet their development goals more efficiently. The ClinForce and Assent businesses will significantly expand our resourcing and FSP capabilities in the US and, when combined with DOCS strong European footprint and growing emerging markets presence, gives us the ability to deliver truly global resourcing solutions. Additionally, AKOS enhances our expertise in the areas of pharmacovigilance and drug safety consulting, which are increasingly important capabilities required by our clients.”

This release contains, and our officers and representatives may from time to time make, "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "expect," "strategy" and similar references to future periods. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results to differ materially from those indicated in the forward-looking statements include, among others, strategic actions, including our success in integrating ClinForce, Assent Consulting and AKOS; general economic and financial conditions; the extent to which we are successful in implementing our strategy, gaining new, long-term relationships with customers and retaining existing ones; the risk of competition on our industry; developments and changes in laws and regulations; and such other factors as discussed in Part I, Item 3 "Risk Factors" in our Form 20-F for the fiscal year ended December 31, 2011. Any forward-looking statement made by us in this release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

About ICON plc
ICON plc is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. The company specialises in the strategic development, management and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies. ICON currently has approximately 9,430 employees, operating from 82 locations in 40 countries.

Further information is available at www.iconplc.com

About Cross Country Healthcare
Cross Country Healthcare, Inc. is a leader in healthcare staffing with a primary focus on providing nurse and allied and physician (locum tenens) staffing services and workforce solutions to the healthcare market. The Company believes it is one of the top two providers of nurse and allied staffing services, one of the top four providers of temporary physician staffing services, and one of the top five providers of retained physician and healthcare executive search services. The Company also is a leading provider of education and training programs specifically for the healthcare marketplace. On a company-wide basis, Cross Country Healthcare has approximately 4,000 contracts with hospitals and healthcare facilities, and other healthcare organizations to provide our staffing services and workforce solutions. Copies of this and other news releases as well as additional information about Cross Country Healthcare can be obtained online at www.crosscountryhealthcare.com. Shareholders and prospective investors can also register to automatically receive the Company's press releases, SEC filings and other notices by e-mail.

Contact Details
ICON
Brendan Brennan
Chief Financial Officer
+ 353-1-291-2000
or
Sam Farthing
VP Investor Relations
+ 353-1-291-2000
All at ICON.

Cross Country Healthcare Completes Sale of Its Clinical Trial Services Business

Today : Tuesday 19 February 2013
Click Here for more Icon Plc - Ordinary Shares (MM) Charts.

Cross Country Healthcare, Inc. (Nasdaq: CCRN) announced today it has completed the previously announced sale of its clinical trial services business to ICON plc (NASDAQ: ICLR) for $52 million, plus an earn-out of up to $3.75 million related to certain performance-based milestones. Cross Country Healthcare used a portion of the net proceeds from this transaction to repay all $29.3 million of its outstanding bank debt.

As a result of this sale, Cross Country Healthcare’s clinical trial services business segment will become discontinued operations and will be reported as such on its financial statements for all applicable periods presented in the Company’s upcoming financial reporting for the fourth quarter and year ended December 31, 2012.

“Our divestiture of this business was based on an extensive review of our operations and the changing landscape in the pharmaceutical R&D outsourcing industry. Having successfully completed this transaction, we will narrow our focus and concentrate our resources on our core nurse and allied staffing and our physician staffing businesses, which pro forma would represent about 90% of our consolidated revenue,” said Joseph A. Boshart, President and Chief Executive Officer of Cross Country Healthcare, Inc. “I also want to wish our outstanding clinical trial service team much success in the future,” added Mr. Boshart.

About Cross Country Healthcare

Cross Country Healthcare, Inc. is a leader in healthcare staffing with a primary focus on providing nurse and allied and physician (locum tenens) staffing services and workforce solutions to the healthcare market. The Company believes it is one of the top two providers of nurse and allied staffing services, one of the top four providers of temporary physician staffing services, and one of the top five providers of retained physician and healthcare executive search services. The Company also is a leading provider of education and training programs specifically for the healthcare marketplace. On a company-wide basis, Cross Country Healthcare has approximately 4,000 contracts with hospitals and healthcare facilities, and other healthcare organizations to provide our staffing services and workforce solutions. Copies of this and other news releases as well as additional information about Cross Country Healthcare can be obtained online at www.crosscountryhealthcare.com. Shareholders and prospective investors can also register to automatically receive the Company's press releases, SEC filings and other notices by e-mail.

About ICON plc

ICON plc is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. The company specialises in the strategic development, management and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies. With headquarters in Dublin, Ireland, ICON currently operates from 82 locations in 40 countries and has approximately 9,500 employees. Further information is available at www.iconplc.com.

In addition to historical information, this press release contains statements relating to our future results (including certain projections and business trends) that are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and are subject to the “safe harbor” created by those sections. Forward-looking statements consist of statements that are predictive in nature, depend upon or refer to future events. Words such as “expects”, “anticipates”, “intends”, “plans”, “believes”, “estimates”, “suggests”, “appears”, “seeks”, “will” and variations of such words and similar expressions intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results and performance to be materially different from any future results or performance expressed or implied by these forward-looking statements. These factors include, without limitation, the following: our ability to attract and retain qualified nurses, physicians and other healthcare personnel, costs and availability of short-term housing for our travel nurses and physicians, demand for the healthcare services we provide, both nationally and in the regions in which we operate, the functioning of our information systems, the effect of existing or future government regulation and federal and state legislative and enforcement initiatives on our business, our clients’ ability to pay us for our services, our ability to successfully implement our acquisition and development strategies, the effect of liabilities and other claims asserted against us, the effect of competition in the markets we serve, our ability to successfully defend the Company, its subsidiaries, and its officers and directors on the merits of any lawsuit or determine its potential liability, if any, and other factors set forth in Item 1A. “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2011, and our other Securities and Exchange Commission filings made during 2012.

Although we believe that these statements are based upon reasonable assumptions, we cannot guarantee future results and readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management’s opinions only as of the date of this press release. There can be no assurance that (i) we have correctly measured or identified all of the factors affecting our business or the extent of these factors’ likely impact, (ii) the available information with respect to these factors on which such analysis is based is complete or accurate, (iii) such analysis is correct or (iv) our strategy, which is based in part on this analysis, will be successful. The Company undertakes no obligation to update or revise forward-looking statements. All references to “we,” “us,” “our,” or “Cross Country” in this press release mean Cross Country Healthcare, Inc., its subsidiaries and affiliates.

ICON Reports Fourth Quarter 2012 Revenue of $300 Million, up 24% year on year, EPS of 34c and Full Year revenue of $1.12 billion, EPS of $1.00.

Highlights — Fourth Quarter and Full year ended December 31 2012.

Quarter 4 net revenue increased 24% year on year to $300 million. Full Year 2012 net revenue increased 18% to $1.12 billion.
Quarter 4 operating income was $24.4 million or 8.1% of revenue. Full Year 2012 operating income before non- recurring charges was $73.7 million or 6.6% of revenue.
Earnings per share for Quarter 4 were $0.34. EPS for the full year 2012 before non-recurring charges was $1.00.
Quarter 4 net business awards were $378 million, a book to bill of 1.26. Full Year net new business awards were $1.6 billion, a book to bill of 1.4.
Backlog increased 20% year on year to $2.8 billion.
Guidance increased to reflect the acquisition of the clinical trial service division of Cross Country Healthcare, Inc. to revenue in the range of $1,258 — $1,292 million and EPS in the range of $1.44 — $1.60.

DUBLIN--(BUSINESS WIRE)-- ICON plc, (NASDAQ: ICLR), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today reported its financial results for the full year and fourth quarter ended December 31, 2012.

For the fourth quarter net revenue grew 24% year on year to $300 million. Operating income was $24.4 million compared to $6.6 million in the same quarter last year. Operating margin was 8.1% of revenue, compared to 2.7% of revenue for the same quarter last year.

Net income was $20.7 million compared with $4.1 million last year or $0.34 per share compared to $0.07 in the same quarter last year.

For the full year revenue grew 18% to $1.12 billion. Operating income before restructuring and other items was $73.7 million compared to $39.3 million last year. Operating margin for the full year 2012 was 6.6% of revenue compared with 4.2% of revenue in 2011.

On a US GAAP basis, income from operations was $68.0 million or 6.1% compared with $29.4 million or 3.1% in the prior year.

For the full year net income before restructuring and other items was $60.4 million, compared to $31.5 million last year and net margin was 5.4% of revenue, compared with 3.3% in 2011.

EPS before restructuring and other items for 2012 was $1.00 per share compared with $0.52 in 2011.

On a US GAAP basis net income was $55.4 million, compared to $22.8 million last year. Net margin for the full year 2012 was 5.0% of revenue, up from 2.4% in 2011. EPS on a US GAAP basis for 2012 was $0.92 per share compared with $0.37 in 2011.

Days sales outstanding, comprising accounts receivable and unbilled revenue less payments on account were 40 days at December 31, 2012 compared with 47 days at December 31, 2011.

For the quarter ended December 31, 2012, cash provided by operating activities was $12.0 million and capital expenditure was $8.4 million. For the full year 2012 cash flow from operating activities was $113.4 million and capital expenditure was $30.8 million. In addition $69.9 million was invested on acquisitions and $15.8 million was expended on a stock repurchase programme. As a result the company's net cash amounted to $190 million at December 31, 2012 compared to $174 million of net cash at December 31, 2011.

On the 15th of February we completed the acquisition of the clinical trial service division of Cross Country Healthcare, Inc. This will be combined with our DOCS group to create a global leader in resourcing. Consequently we have increased our full year guidance to revenue in the range of $1,258- $1,292 and EPS in the range of $1.44 - $1.60.

CEO Ciaran Murray commented, "In 2012 we saw the validation of our investment strategy as we won a record $1.6 billion of new business and reported milestone revenue of $1.12 billion and EPS of $1.00. Backlog grew 20% to $2.8 billion, which along with continuing investment in capabilities, talent and innovation in drug development, provides a solid foundation for further growth in 2013."

In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), this press release contains certain non-GAAP financial measures, including non-GAAP operating and net income and non-GAAP diluted earnings per share. While non-GAAP financial measures are not superior to or a substitute for the comparable GAAP measures, ICON believes certain non-GAAP information is useful to investors for historical comparison purposes.

ICON will hold its fourth quarter conference call today, February 19, 2013 at 9:00 EST [14:00 Ireland & UK]. This call and linked slide presentation can be accessed live from our website at http://investor.iconplc.com. A recording will also be available on the website for 90 days following the call. In addition, a calendar of company events, including upcoming conference presentations, is available on our website, under "Investors". This calendar will be updated regularly.

The statements made in this press release may contain forward-looking statements that involve a number of risks and uncertainties. In addition to the matters described in this press release, the ability to maintain large client contracts or enter into new contracts, maintain client relationships and the ability to manage the opening of new offices, the integration of new business mergers and acquisitions, as well as other risks and uncertainties detailed from time to time in reports filed with the US Securities and Exchange Commission by ICON, including its Form 20-F, F-1, S-8 and F-3, may affect the actual results achieved by ICON. ICON disclaims any intent or obligation to update these forward-looking statements.

ICON plc is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. The company specialises in the strategic development, management and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies. With headquarters in Dublin, Ireland, ICON currently, operates from 79 locations in 37 countries and has approximately 10,045 employees. Further information is available at www.iconplc.com.